Results 21 to 30 of about 1,515,353 (171)

The effect of Elettaria cardamomum (cardamom) on the metabolic syndrome: Narrative review [PDF]

Iranian Journal of Basic Medical Sciences, 2021
Metabolic syndrome (MetS), as a health-threatening factor, consists of various symptoms including insulin resistance, high blood sugar, hypertension, dyslipidemia, inflammation, and abdominal obesity that raise the risk of diabetes mellitus and ...
Roghayeh Yahyazadeh, Mahboobeh Ghasemzadeh Rahbardar, Bibi Marjan Razavi, Gholamreza Karimi, Hossein Hosseinzadeh   +4 more
doaj   +1 more source

Persistence and Adherence to Cardiovascular Medicines in Australia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background The burden of cardiovascular disease is increasing, with many people treated for multiple cardiovascular conditions. We examined persistence and adherence to medicines for cardiovascular disease treatment or prevention in Australia.
Juliana de Oliveira Costa, Jialing Lin, Sallie‐Anne Pearson, Nicholas A. Buckley, Andrea L. Schaffer, Michael O. Falster   +5 more
doaj   +1 more source

Unlocking the Medicinal Mysteries: Preventing Lacunar Stroke with Drug Repurposing

Biomedicines, 2023
Currently, only the general control of the risk factors is known to prevent lacunar cerebral infarction, but it is unknown which type of medication for controlling the risk factors has a causal relationship with reducing the risk of lacunar infarction ...
Linjing Zhang, Fan Wang, Kailin Xia, Zhou Yu, Yu Fu, Tao Huang, Dongsheng Fan   +6 more
doaj   +1 more source

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

Frontiers in Cardiovascular Medicine, 2022
BackgroundAtherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs.
Vivencio Barrios, Vivencio Barrios, Mar Castellanos, Mar Castellanos, Raquel Campuzano Ruiz, Jorge Francisco Gómez Cerezo, Isabel Egocheaga Cabello, José M. Gámez, José M. Gámez, Icíar Martínez López, José María Mostaza, Nuria Morant Talamante, Javier Parrondo, Aram Sicras Navarro, Inés Pérez Román, Antoni Sicras-Mainar, Vicente Pallarés-Carratalá, Vicente Pallarés-Carratalá   +17 more
doaj   +1 more source

Associations between education level, blood-lipid measurements and statin treatment in a Danish primary health care population from 2000 to 2018

Scandinavian Journal of Primary Health Care, 2023
Objective To examine whether education level influences screening, monitoring, and treatment of hypercholesterolemia.Design Epidemiological cohort study.Setting Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre.Subjects ...
Marius Mølsted Flege, Margit Kriegbaum, Henrik Løvendahl Jørgensen, Bent Struer Lind, Lise Bathum, Christen Lykkegaard Andersen, Anna Elise Engell   +6 more
doaj   +1 more source

Extreme lipoprotein(a) in clinical practice: A cross sectional study

International Journal of Cardiology. Cardiovascular Risk and Prevention, 2023
Introduction: Measurement of lipoprotein(a) [Lp(a)] is recommended once in a lifetime to identify individuals at high risk of atherosclerotic cardiovascular disease (ASCVD).
Barak Zafrir, Amir Aker, Walid Saliba
doaj   +1 more source

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines

Безопасность и риск фармакотерапии, 2023
Scientific relevance. Cardiovascular diseases (CVD) are the leading cause of death worldwide. Dyslipidemia, as the pathophysiological basis of atherosclerosis, is the most important cause of CVD.
A. A. Nekipelova, R. N. Alyautdin
doaj   +1 more source

Novel Hypolipidemic Agents: Focus on PCSK9 Inhibitors [PDF]

, 2013
Proprotein convertase subtilisin/kexin type 9 (PCSK9) was recently discovered as the third gene involved in autosomal dominant familial hypercholesterolemia.
Manolis, Theodora A, Melita, Helen, Manolis, Antonis S   +2 more
core   +1 more source

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Journal of Cardiovascular Development and Disease, 2022
Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially ...
Tomoaki Okada, Toru Miyoshi, Masayuki Doi, Kazumasa Nosaka, Ryu Tsushima, Satoko Ugawa, Wataru Takagi, Masahiro Sogo, Masahiko Takahashi, Hiroshi Ito   +9 more
doaj   +1 more source

Inhibition of palmitoyl CoA deacylase by chlorophenoxyisobutyrate and betabenzalbutyrate

Journal of Lipid Research, 1973
Palmitoyl CoA deacylase activity was measured in preparations of rat liver microsomes. Two hypolipidemic agents, chlorophenoxyisobutyrate and betabenzalbutyrate caused inhibition of palmitoyl CoA deacylase in vitro.
Robert G. Lamb, Patsy M. Hill, Harold J. Fallon   +2 more
doaj   +1 more source